✨ Your Portfolio is fetched and updated from zerodha.

Jubilant Pharmova Ltd.

JUBLPHARMA

Market Cap
₹17,471 Cr.
P/E
29.46

Jubilant Pharmova Ltd.

  • Jubilant Pharmova
  • Caplin Point Lab
  • Eris Lifesciences
  • TJI Pharma - API & CRAMS
FAQs on Jubilant Pharmova Ltd. Shareprice

Jubilant Pharmova has given lower returns compared to its competitors.
Jubilant Pharmova has grown at ~4.93% over the last 7yrs while peers have grown at a median rate of 12.98%

Jubilant Pharmova is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Jubilant Pharmova is 29.46, while 3 year average PE is 39.66.
Also latest EV/EBITDA of Jubilant Pharmova is 18.65 while 3yr average is 11.15.

View FAQ's On Business
Growth Table
  • Jubilant Pharmova Ltd.
  • Caplin Point Lab
  • Eris Lifesciences
Balance Sheet
  • Jubilant Pharmova Ltd.
  • Caplin Point Lab
  • Eris Lifesciences
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Jubilant Pharmova Ltd.
  • Caplin Point Lab
  • Eris Lifesciences
Cash Flow
  • Jubilant Pharmova Ltd.
  • Caplin Point Lab
  • Eris Lifesciences
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Jubilant Pharmova Ltd.
  • Caplin Point Lab
  • Eris Lifesciences
Quarterly Results
  • Jubilant Pharmova Ltd.
  • Caplin Point Lab
  • Eris Lifesciences
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Jubilant Pharmova Ltd. Financials

Balance sheet of Jubilant Pharmova is strong.
It shouldn't have solvency or liquidity issues.

Yes, The debt of Jubilant Pharmova is increasing.
Latest debt of Jubilant Pharmova is ₹1,748 Crs as of Sep-24.
This is greater than Mar-24 when it was ₹1,502 Crs.

Yes, profit is increasing.
The profit of Jubilant Pharmova is ₹572 Crs for TTM, ₹77.1 Crs for Mar 2024 and -₹61 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Jubilant Pharmova latest dividend payout ratio is 102.46% and 3yr average dividend payout ratio is 60.85%

Companies resources are majorly tied in miscellaneous assets

View FAQ's On Shareholding
timeline Timeline
watchlist Watchlist
portfolio Portfolio
alerts Alerts
filter Research
filter Stock Screener
markets Market
raw materials Raw Material
Data feed provided by Accord Fintech